Emily K Schworer, Benjamin L Handen, Melissa Petersen, Sid O'Bryant, Jamie C Peven, Dana L Tudorascu, Laisze Lee, Sharon J Krinsky-McHale, Christy L Hom, Isabel C H Clare, Bradley T Christian, Nicole Schupf, Joseph H Lee, Elizabeth Head, Mark Mapstone, Ira Lott, Beau M Ances, Shahid Zaman, Adam M Brickman, Florence Lai, H Diana Rosas, Sigan L Hartley
INTRODUCTION: People with Down syndrome (DS) have a 75% to 90% lifetime risk of Alzheimer's disease (AD). AD pathology begins a decade or more prior to onset of clinical AD dementia in people with DS. It is not clear if plasma biomarkers of AD pathology are correlated with early cognitive and functional impairments in DS, and if these biomarkers could be used to track the early stages of AD in DS or to inform inclusion criteria for clinical AD treatment trials. METHODS: This large cross-sectional cohort study investigated the associations between plasma biomarkers of amyloid beta (Aβ)42/40, total tau, and neurofilament light chain (NfL) and cognitive (episodic memory, visual-motor integration, and visuospatial abilities) and functional (adaptive behavior) impairments in 260 adults with DS without dementia (aged 25-81 years)...
2024: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring